Research Paper Volume 13, Issue 20 pp 23579—23587

AHNAK suppresses ovarian cancer progression through the Wnt/β-catenin signaling pathway

AHNAK is downregulated in ovarian cancer. (A) AHNAK expression pattern across all tumor samples and matched non-malignant samples. (B) AHNAK expression levels in 30 serous ovarian cancer tissues and paired non-malignant tissues. **p C) Images illustrating immunohistochemical staining of AHNAK content in two pairs of paired ovarian cancer samples and their neighboring non-malignant tissue. Original magnification, 200X.

Figure 1. AHNAK is downregulated in ovarian cancer. (A) AHNAK expression pattern across all tumor samples and matched non-malignant samples. (B) AHNAK expression levels in 30 serous ovarian cancer tissues and paired non-malignant tissues. **p < 0.01. (C) Images illustrating immunohistochemical staining of AHNAK content in two pairs of paired ovarian cancer samples and their neighboring non-malignant tissue. Original magnification, 200X.